Liling Zhang: Clinical Trials

2 trials sponsored by Liling Zhang, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Recruiting 2

Follow Liling Zhang: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden
Glofitamab + Obinutuzumab - Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma
Phase 2RecruitingLiling Zhang402025-04-012026-05-15
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Duvelisib, Chidamide - Newly Diagnosed Peripheral T-cell Lymphoma
Phase 2RecruitingLiling Zhang362023-05-082026-05-18

Conditions studied

Lymphoma (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, T-Cell, Peripheral (1)

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1)  ·  duvelisib (1)  ·  glofitamab (1)  ·  obinutuzumab (1)

Countries

China (2)